Paper37558752
Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles.
Rojas G and 19 others. Commun Biol, 2023. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles. Papers, record 37558752. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37558752
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Peptide Library | Major topic |
| Interleukin-2 Receptor beta Subunit | Major topic |
| Interleukin-2 | Major topic |
| Directed Molecular Evolution | Major topic |
| Humans | |
| Recombinant Fusion Proteins | |
| Protein Domains | |
| Animals | |
| Mice | |
| Cell Line, Tumor |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20195250 | Waltz, an exciting new move in amyloid prediction. | Nat Methods | 2010 | https://conductscience.org/library/papers/20195250 | PubMed |
| 2 | 3881765 | Rapid and efficient site-specific mutagenesis without phenotypic selection. | Proc Natl Acad Sci U S A | 1985 | https://conductscience.org/library/papers/3881765 | PubMed |
| 3 | 35588144 | Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I+ tumors. | Proc Natl Acad Sci U S A | 2022 | https://conductscience.org/library/papers/35588144 | PubMed |
| 4 | 23677467 | Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. | J Immunol | 2013 | https://conductscience.org/library/papers/23677467 | PubMed |
| 5 | 14983090 | Interleukin-2 mutants with enhanced alpha-receptor subunit binding affinity. | Protein Eng | 2003 | https://conductscience.org/library/papers/14983090 | PubMed |
| 6 | 34526724 | An engineered IL-2 partial agonist promotes CD8+ T cell stemness. | Nature | 2021 | https://conductscience.org/library/papers/34526724 | PubMed |
| 7 | 25873172 | Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25873172 | PubMed |
| 8 | 22791129 | Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active. | Protein J | 2012 | https://conductscience.org/library/papers/22791129 | PubMed |
| 9 | 16823375 | Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. | Nat Biotechnol | 2006 | https://conductscience.org/library/papers/16823375 | PubMed |
| 10 | 22343569 | The role of interleukin-2 during homeostasis and activation of the immune system. | Nat Rev Immunol | 2012 | https://conductscience.org/library/papers/22343569 | PubMed |
| 11 | 16477002 | Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16477002 | PubMed |
| 12 | 16505437 | Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. | J Clin Oncol | 2006 | https://conductscience.org/library/papers/16505437 | PubMed |
| 13 | 15215442 | Protein structure prediction and analysis using the Robetta server. | Nucleic Acids Res | 2004 | https://conductscience.org/library/papers/15215442 | PubMed |
| 14 | 23802841 | High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. | BMC Biotechnol | 2013 | https://conductscience.org/library/papers/23802841 | PubMed |
| 15 | 30692603 | Directed evolution of super-secreted variants from phage-displayed human Interleukin-2. | Sci Rep | 2019 | https://conductscience.org/library/papers/30692603 | PubMed |
| 16 | 20732639 | Interleukin-2 receptor signaling: at the interface between tolerance and immunity. | Immunity | 2010 | https://conductscience.org/library/papers/20732639 | PubMed |
| 17 | 29116526 | Phagekines: Screening Binding Properties and Biological Activity of Functional Cytokines Displayed on Phages. | Methods Mol Biol | 2018 | https://conductscience.org/library/papers/29116526 | PubMed |
| 18 | 23168257 | Cellular strategies for regulating functional and nonfunctional protein aggregation. | Cell Rep | 2012 | https://conductscience.org/library/papers/23168257 | PubMed |
| 19 | 24515482 | Fine epitope mapping based on phage display and extensive mutagenesis of the target antigen. | Methods Mol Biol | 2014 | https://conductscience.org/library/papers/24515482 | PubMed |
| 20 | 7608166 | Ligand binding analysis of soluble interleukin-2 receptor complexes by surface plasmon resonance. | J Biol Chem | 1995 | https://conductscience.org/library/papers/7608166 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42469290 | CD25 genetic ablation on lymphoid cell lines to obtain models of stimulation through the Interleukin-2 beta/gamma receptor. | Sci Rep | 2026 | https://conductscience.org/library/papers/42469290 | PubMed |
| 40284529 | A Convenient Strategy for Studying Antibody Aggregation and Inhibition of Aggregation: Characterization and Simulation. | Pharmaceutics | 2025 | https://conductscience.org/library/papers/40284529 | PubMed |
| 40219553 | [Biological activity and antitumor effect of long-acting recombinant human interleukin-2 drug]. | Beijing Da Xue Xue Bao Yi Xue Ban | 2025 | https://conductscience.org/library/papers/40219553 | PubMed |
| 40201389 | Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/40201389 | PubMed |
| 40190571 | Directed disruption of IL2 aggregation and receptor binding sites produces designer biologics with enhanced specificity and improved production capacity. | Comput Struct Biotechnol J | 2025 | https://conductscience.org/library/papers/40190571 | PubMed |
| 39852848 | Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies. | Vaccines (Basel) | 2025 | https://conductscience.org/library/papers/39852848 | PubMed |
| 38184672 | Studying SARS-CoV-2 interactions using phage-displayed receptor binding domain as a model protein. | Sci Rep | 2024 | https://conductscience.org/library/papers/38184672 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data1
The data bank entries PubMed's record names. Trial numbers are under Trials.
| Data bank | Accession |
|---|---|
| Dryad | 10.5061/dryad.kh18932c8 |
Source Dryad
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37558752
GET https://conductscience.org/api/papers/v1/37558752/references?page=2